1. Scrip
  2. >>New Products

Wegovy Starting Doses Restrictions Will Continue Through The Year

 
• By Jessica Merrill

Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.

supply and demand
Supply for Wegovy will continue to be tight this year • Source: Shutterstock

Novo Nordisk A/S updated investors on the ongoing supply constraints for its big-selling weight loss drug Wegovy (semaglutide) on 10 August, indicating restrictions on new patient starts in the US will continue throughout the rest of the year.

The news came just two days after announcing positive topline cardiovascular data showing the drug can reduce cardiovascular risks like heart attack, stroke and death – which is expected to broaden coverage by US payers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.